Skip to main content

Market Overview

The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs

Share:
The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs

Biotech stocks reversed course in the week ended April 16, with the sector rebounding along with the broader market. The week's news flow was fairly light. The American Association of Cancer Research's annual meeting provided a platform for oncology-focused biopharma companies to present data from their clinical programs.

A negative headline on COVID-19 vaccine, however, marred the week. The Food and Drug Administration and the Centers for Disease Control and Prevention announced their recommendation to pause the use of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine following incidences of severe clots.

J&J's pain turned into  gains for other COVID-19 vaccine companies. Moderna, Inc. (NASDAQ: MRNA) added about 20% during the week, with positive preclinical data on variant-specific COVID-19 vaccines and positive analyst actions adding strength to the rally.

Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares spiked ahead of the PDUFA date for its pain drug. With the company announcing Tuesday it has not heard yet from the FDA and the review is continuing, the shares lost about 42% for the week from Monday's intra-day high of $7.54.

Here are the key catalysts for the unfolding week:

Conferences

American Academy of Neurology, or AAN, 2021 Annual Meeting (virtual): April 17-22
Bloom Burton & Co. Healthcare Investor Conference: April 20-21

Clinical Readouts/Presentations

AAN Meeting Presentations

Prothena Corporation plc (NASDAQ: PRTA): results from the Phase 1 study of PRX004 in ATTR amyloidosis, a rare disorder that occurs when there is a buildup of amyloid proteins in the body (Sunday, at 3-4:30 p.m.)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY): full 9-month results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi drug for treating polyneuropathy of hereditary ATTR amyloidosis, a genetic disorder affecting a protein called transthyretin, produced in the liver (Monday, 2 p.m.)

Standalone Releases

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) will host a conference call and live webcast at 8 a.m. on Tuesday to provide updated data from the Phase 1 dose escalation portion of its ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with relapsed or refractory acute leukemias.

Related Link: Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company's Pipeline

Earnings

Tuesday

Johnson & Johnson (before the market open)
Abbott Laboratories (NYSE: ABT) (before the market open)
Intuitive Surgical, Inc. (NASDAQ: ISRG) (after the close)

Thursday

Biogen Inc. (NASDAQ: BIIB) (before the market open)
Quest Diagnostics Incorporated (NASDAQ: DGX) (before the market open)

IPOs

IPO Pricing

Mountainview, California-based Neuropace Inc. has filed with the SEC to offer 5.313 million shares in an initial public offering, priced between $15 and $17. The commercial-stage medical device company manufactures brain-responsive neuromodulation system for epilepsy treatment. Neurospace expects to list its common stock on the Nasdaq under the ticker symbol NPCE.

Zymergen Inc. is an Emeryville, California-based company that engineers microbes to make novel biomolecules used in various products. The company proposes to offer 13.6 million shares at an estimated price range of $28-$31. The company has applied for listing its shares on the Nasdaq under the ticker symbol ZY.

IPO Quiet Period Expiry

Lava Therapeutics B.V. (NASDAQ: LVTX)
Design Therapeutics, Inc. (NASDAQ: DSGN)
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
Ikena Oncology, Inc. (NASDAQ: IKNA)
Achilles Therapeutics plc (NASDAQ: ACHL)

Related Link: Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates

Photo by Thought Catalog on Unsplash

 

Related Articles (IBB)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Penny Stocks Previews Small Cap IPOs Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com